Skip to content

Microneedling effect on male baldness.

Randomized comparative single blinded clinical trial on the effectiveness and safety of microneedling in the treatment of androgenetic alopecia.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-3cjbq5
Enrollment
Unknown
Registered
2020-05-26
Start date
2020-10-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenetic alopecia

Interventions

Group A: 10 participants will receive microneedling in 1 hemiface of the scalp and will not use any home medication. Group B: 10 participants will receive microneedling in 1 hemiface of the scalp and
Drug
Procedure/surgery

Sponsors

Hospital São Paulo
Lead Sponsor
Hospital São Paulo
Collaborator

Eligibility

Sex/Gender
Male
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Signature of Written Informed Consent Form and Authorization for Photographs Term prior to any study procedure; men aged between 18 and 60 years, in good health; Clinical diagnosis of moderate male androgenet alopecia (Stage IIIa-IV of the Norwood-Hamilton Scale) with disease onset time less than 10 years; accordance with the conditions of the study, ability to understand and strictly follow the therapeutic guidelines received and availability to attend periodic evaluations.

Exclusion criteria

Exclusion criteria: Men who do not agree with the conditions of the study or who are unable to understand and strictly follow the therapeutic guidelines received, are not available to attend periodic evaluations or refuse to sign the Written Informed Consent Form and Authorization for Photographs Term; patients suffering from other alopecias, including telogen effluvium; patients with mild disease (stages I and II) or severe disease (stages V to VII of the Norwood-Hamilton Scale); patients who have androgenetic alopecia for more than 10 years; previous use of finasteride or dutasteride in the last 6 months; patients with a current or previous history of malignant or pre-malignant tumors of the scalp; patients that suffer from allergic contact dermatitis to propylene glycol (minoxidil vehicle), minoxidil, tattoo ink, topical or local anesthetic; patients that have dermatoses that may worsen due to the procedure and interfere with the evaluation, such as psoriasis, vitiligo; patients receiving chemotherapy, radiation therapy, corticosteroids or other immunosuppressants.

Design outcomes

Primary

MeasureTime frame
Expected outcome 1:Increased hair thickness and follicular density (hairs/cm2) in the halfhead submeted to intervention comparing data from baseline and two weeks after the final intervention. Analysis of the trichoscopic images will be performed using TrichoLAB Hair-to-Hair Matching technology.;Expected outcome 2:Increased hair thickness and follicular density (hairs/cm2) in the halfhead submeted to intervention comparing data from baseline and sexteen weeks after the final intervention. Analysis of the trichoscopic images will be performed using TrichoLAB Hair-to-Hair Matching technology.

Secondary

MeasureTime frame
Secondary outcomes are not expected.

Countries

Brazil

Contacts

Public ContactAline Blanco Barbosa

Hospital São Paulo

alibbarbosa@yahoo.com.br+55-67-999639593

Outcome results

None listed

Source: REBEC (via WHO ICTRP)